MedTrace Logo

Daily Versus Alternate Day Regimen of Iron Supplementation in Children with Iron Deficiency Anemia

NCT06631612 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2024-10-08

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if giving iron supplementation every other day is as effective as giving it daily in children with Iron Deficiency Anemia.

The main questions it aims to answer are:

1. Will alternate day regimen improve hemoglobin and iron profile just as well as daily dose?
2. Which group will suffer less side effects from Iron Supplementation?

Participants will be divided into two groups:

Group A: will receive oral Iron supplementation daily for 2 months Group B: will receive oral Iron supplementation every other day for 2 months Participants will be monitored using weekly phone calls to insure compliance and report side effects.

Both groups will be given Albendazole 400 mg once at the beginning of the study to be repeated in 1 week

Conditions

  • Iron Deficiency Anemia Treatment

Interventions

DRUG

ferric hydroxide polymaltose complex

participants will receive oral iron supplementation according to body weight every other day

DRUG

ferric hydroxide polymaltose complex

participants will receive oral iron supplementation dose according to body weight daily

DRUG

Albendazole.

both arms will receive Albendazole 400mg once at the beginning f the study to be repeated after 1 week

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Wessam A Professor, MD · Ain Shams Pediatrics Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2025-01-31
Completion
2025-03-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06631612 on ClinicalTrials.gov